Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 3/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 9/20 | 0.38 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL250212 | 1.00 | MEN1 (0.39) | MEN1MAPTKMT2AEGFRPDCD1 | |
| SCHEMBL206869 | 0.90 | S1PR1 (0.44) | MEN1MAPTKMT2ASLC6A9S1PR1 | |
| SCHEMBL205790 | 0.90 | S1PR1 (0.44) | MEN1MAPTKMT2ASLC6A9S1PR1 | |
| SCHEMBL206328 | 0.90 | S1PR1 (0.44) | MEN1MAPTKMT2ASLC6A9S1PR1 | |
| SCHEMBL248422 | 0.86 | S1PR5 (0.49) | MEN1MAPTKMT2AEGFRCD274 | |
| SCHEMBL250377 | 0.85 | SPHK1 (0.47) | EGFRENPP2SPHK1 | |
| SCHEMBL253248 | 0.82 | MAPT (0.40) | MEN1MAPTKMT2AEGFRS1PR4 | |
| SCHEMBL253249 | 0.82 | MAPT (0.40) | MEN1MAPTKMT2AEGFRS1PR4 | |
| SCHEMBL248468 | 0.82 | SPHK1 (0.43) | MEN1MAPTKMT2AEGFRS1PR4 | |
| SCHEMBL205846 | 0.81 | LMNA (0.46) | MEN1MAPTKMT2AEGFRSPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8088806-B2 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20070004711-A1 | Thiazole compounds and methods of use | ACHILLION PHARMACEUTICALS, INC. | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108576-A1 | THIAZOLE COMPOUNDS AND METHODS OF USE | PIGS, CPT1A, SLC10A1 | MEN1 3862/4885MAPT 2207/4885KMT2A 3476/4885 |
| US-20070004711-A1 | Thiazole compounds and methods of use | PIGS, CPT1A, SLC10A1 | MEN1 3862/4885MAPT 2207/4885KMT2A 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.